Client Rights

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline as Securities Case Advances in SDNY

Plaintiffs allege MoonLake overstated sonelokimab’s Nanobody benefits in light of Phase 3 results that failed to show superior efficacy.